Trump's Marijuana Rescheduling Push Is Back in Focus. Is Tilray Stock Finally a Buy?
Key PointsRescheduling could expand Tilray’s U.S. medical cannabis opportunity.
President Donald Trump has reignited efforts to reschedule marijuana, with federal officials now under orders to expedite the process. This move has weathered another legal challenge, as a recent federal appeals court decision has blocked opponents from halting the administration's progress. While the ruling does not guarantee marijuana will ultimately be reclassified from Schedule I to Schedule III, it does ensure the process remains in motion.
For those watching the marijuana market, Tilray Brands (NASDAQ: TLRY) may be a stock to keep an eye on should the rescheduling occur. It's important to note that moving marijuana to Schedule III would not federally legalize recreational cannabis or allow Tilray to start shipping Canadian recreational products into the U.S. However, it would signify a significant shift in federal marijuana policy over the past few decades.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
